A Study in Adult Subjects With Select Advanced Solid Tumors

This is a first-time-in-human, Phase 1, multicenter, open-label, single-arm dose-escalation
study of MEDI1873 to evaluate the safety, tolerability, pharmacokinetics, immunogenicity,
pharmacodynamics and anti-tumor activity in adult subjects with advanced solid tumor
malignancies

Inclusion Criteria:

- All subjects must consent to provide archived tumor specimen

- Subjects must have histologically or cytologically confirmed advanced solid tumor for
recurrent or metastatic disease.

- At the time of Day 1 of the study, subjects with central nervous system (CNS)
metastases must have been treated and must be asymptomatic

- Willingness to provide pretreatment and on-treatment biopsies.

- Adequate organ function

- Females of childbearing potential and nonsterilized males who are sexually active must
use effective methods of contraception

Exclusion Criteria:

- Known allergic reaction to any component of MEDI1873

- Concurrent enrollment in another clinical study, unless it is an observational
clinical study or the follow-up period of an interventional study

- Receipt of any anticancer therapy within 4 weeks prior to the first dose of MEDI1873;
in the case of mAbs, 6 weeks prior to the first dose of MEDI1873

- Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer
treatment.

- Receipt of live, attenuated vaccine within 28 days prior to the first dose of
investigational product

- Unresolved toxicities from prior anticancer therapy

- Any condition that, in the opinion of the investigator or sponsor, would interfere
with evaluation of the investigational product.